NYSE:PBH - Prestige Consumer Healthcare Stock Price, News, & Analysis

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare Inc (NYSE:PBH) issued its earnings results on Thursday, February, 7th. The company reported $0.73 EPS for the quarter, beating the Zacks' consensus estimate of $0.71 by $0.02. The business earned $241.40 million during the quarter, compared to analysts' expectations of $241.40 million. Prestige Consumer Healthcare had a net margin of 6.44% and a return on equity of 11.85%. The company's quarterly revenue was down 10.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.70 earnings per share. View Prestige Consumer Healthcare's Earnings History.

Prestige Consumer Healthcare is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Prestige Consumer Healthcare.

Prestige Consumer Healthcare issued an update on its FY19 earnings guidance on Thursday, February, 7th. The company provided earnings per share (EPS) guidance of $2.75-$2.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.76. The company issued revenue guidance of $970-$975 million, compared to the consensus revenue estimate of $971.99 million.Prestige Consumer Healthcare also updated its FY 2019 guidance to $2.75-2.78 EPS.

5 brokerages have issued 12 month price objectives for Prestige Consumer Healthcare's stock. Their predictions range from $28.40 to $97.00. On average, they expect Prestige Consumer Healthcare's stock price to reach $57.88 in the next twelve months. This suggests a possible upside of 106.1% from the stock's current price. View Analyst Price Targets for Prestige Consumer Healthcare.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prestige Consumer Healthcare.

Media coverage about PBH stock has been trending positive recently, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Prestige Consumer Healthcare earned a news sentiment score of 2.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the next few days.

Some companies that are related to Prestige Consumer Healthcare include Nektar Therapeutics (NKTR), Alkermes (ALKS), Patheon (PTHN), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Evotec (EVTCY), Amneal Pharmaceuticals (AMRX) and ACADIA Pharmaceuticals (ACAD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Micron Technology (MU), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), AbbVie (ABBV), Cara Therapeutics (CARA), Dropcar (DCAR), Rigel Pharmaceuticals (RIGL), Boeing (BA), Edwards Lifesciences (EW) and Merck & Co., Inc. (MRK).

Prestige Consumer Healthcare's stock is owned by many different of retail and institutional investors. Top institutional investors include Dalton Greiner Hartman Maher & Co. (0.74%), First Manhattan Co. (0.72%), Skyline Asset Management LP (0.64%), Retirement Systems of Alabama (0.41%), Tibra Equities Europe Ltd (0.04%) and Meeder Asset Management Inc. (0.04%). Company insiders that own Prestige Consumer Healthcare stock include Gary E Costley, Jean A Boyko, Natale S Ricciardi, Ronald M Lombardi, Timothy Connors and William P'pool. View Institutional Ownership Trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including Skyline Asset Management LP, First Manhattan Co. and Dalton Greiner Hartman Maher & Co.. Company insiders that have sold Prestige Consumer Healthcare company stock in the last year include Jean A Boyko and Timothy Connors. View Insider Buying and Selling for Prestige Consumer Healthcare.

PBH stock was purchased by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Tibra Equities Europe Ltd, Eqis Capital Management Inc., Meeder Asset Management Inc., First Citizens Bank & Trust Co. and Financial Gravity Wealth Inc.. Company insiders that have bought Prestige Consumer Healthcare stock in the last two years include Gary E Costley, Natale S Ricciardi, Ronald M Lombardi and William P'pool. View Insider Buying and Selling for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $28.08.

Prestige Consumer Healthcare has a market capitalization of $1.45 billion and generates $1.04 billion in revenue each year. The company earns $339.57 million in net income (profit) each year or $2.58 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe.

The official website for Prestige Consumer Healthcare is http://www.prestigebrands.com.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]